Pill with imprint 736 2 mg is Yellow & White, Capsule/Oblong and has been identified as Terazosin Hydrochloride 2 mg. It is supplied by Chartwell RX, LLC. Terazosin is used in the treatment of Benign Prostatic Hyperplasia; High Blood Pressure and belongs to the drug classes alpha blockers, antiadrenergic agents, peripherally acting.

Pill Identifier results for "736 2mg". Search by imprint, shape, color or drug name.

Terazosin Capsules, USP 2 mg, are available as size 3 yellow opaque cap and white opaque body hard gelatin capsules, imprinted with "736" on the cap and "2 mg" on the body in black ink, packaged in bottles of 100 and 1000 capsules, NDC # 23155-736-01 and NDC # 23155-736-10.

View images of terazosin and identify pills by imprint code, shape and color with the Drugs.com Pill Identifier.

Feb 1, 2025 · Terazosin is used to treat men who have symptoms of an enlarged prostate gland, which is also known as benign prostatic hyperplasia (BPH). When the prostate gland gets larger, certain muscles in the gland get in the way of the tube that drains urine from the bladder.

Terazosin Capsules, USP 2 mg, are available as size 3 yellow opaque cap and white opaque body hard gelatin capsules, imprinted with "736" on the cap and "2 mg" on the body in black ink, packaged in bottles of 90 capsules, NDC # 62135-459-90.

Terazosin is used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia or BPH), which include difficulty urinating (hesitation, dribbling, weak stream, and incomplete bladder emptying), painful urination, and urinary frequency and urgency.

Feb 1, 2025 · Terazosin capsules, USP, for oral administration, are supplied in four dosage strengths containing terazosin hydrochloride, USP equivalent to 1 mg, 2 mg, 5 mg, or 10 mg of terazosin. Inactive ingredients: Crospovidone, lactose (monohydrate), magnesium stearate, and microcrystalline cellulose.

Terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin.

Terazosin is used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia or BPH), which include difficulty urinating (hesitation, dribbling, weak stream, and incomplete bladder emptying), painful urination, and urinary frequency and urgency.